Target intelligence / Profile preview

Nitric oxide synthase 1 mRNA (NOS1 mRNA)

Target
NOS1 mRNA
Molecular classification
Messenger RNA, Nucleic acid
01

Overview

Nitric oxide synthase 1 (NOS1) mRNA is the messenger RNA transcript that encodes the neuronal isoform of the enzyme nitric oxide synthase (nNOS). This enzyme is responsible for the production of nitric oxide (NO), a critical gaseous signaling molecule involved in neurotransmission, synaptic plasticity, and the regulation of smooth muscle tone in the gastrointestinal and respiratory tracts (UniProt P29475; NCBI Gene ID: 4842). Dysregulation of NOS1 mRNA expression is implicated in several pathological states, including neurodegenerative disorders like Alzheimer's and Parkinson's diseases, where excessive NO production contributes to oxidative stress and neuronal death (Zhou & Zhu, 2009). Additionally, altered NOS1 mRNA levels are linked to chronic pain conditions and psychiatric disorders such as schizophrenia. Targeting the mRNA transcript using antisense oligonucleotides (ASOs) or RNA interference (RNAi) offers a highly specific therapeutic approach to downregulate nNOS expression without affecting other isoforms like endothelial (eNOS) or inducible (iNOS) nitric oxide synthase. Preclinical studies have explored these RNA-targeted strategies to mitigate neurotoxicity and hyperalgesia in various disease models (Ishii et al., 2002).

Other names
nNOS mRNANeuronal nitric oxide synthase mRNANOS-I mRNAbNOS mRNANitric oxide synthase 1 (neuronal) transcript
02

Mechanism of action

Antisense inhibition or RNA interference (RNAi) targeting the NOS1 mRNA sequence to induce degradation or block translation, thereby reducing the cellular levels of the Nitric oxide synthase 1 protein.

03

Biological functions

Translation of Nitric oxide synthase 1 proteinRegulation of nitric oxide synthesisNeurotransmissionSynaptic plasticitySmooth muscle relaxationLong-term potentiation
04

Disease associations

Neurodegenerative diseaseAlzheimer's diseaseParkinson's diseaseChronic painSchizophreniaAsthmaInfantile hypertrophic pyloric stenosis
05

Safety considerations

Off-target effects of oligonucleotide-based therapiesDisruption of physiological nitric oxide signaling in the central and peripheral nervous systemsPotential for systemic toxicityChallenges in blood-brain barrier penetration for CNS-specific targetingPotential for unintended immune response to synthetic nucleic acids
06

Interacting drugs

Antisense oligonucleotides (experimental)

1 more in the full profile.

07

Biomarkers

NOS1 mRNA expression levels (via RT-qPCR)Nitric oxide (NO) concentrationNOS1 protein levelsCyclic guanosine monophosphate (cGMP) levels

Beyond the preview

Go deeper on Nitric oxide synthase 1 mRNA (NOS1 mRNA).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Nitric oxide synthase 1 mRNA (NOS1 mRNA).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call